The British Pharmacopoeia 2026 edition: Setting the standard for tomorrow
If you're preparing for a regulatory submission, scaling production, validating methods, or ensuring clinical trial consistency, having a reliable and compliant process is essential.
The British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes approximately 4,000 monographs, which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph.
All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and internationally.
New for the BP 2026 edition:
- 19 new BP monographs and 34 new monographs reproduced from the 11th edition of the Ph. Eur., as amended by issues 11.6 to 11.8
- Two new appendices, four supplementary chapters, and six new infrared reference spectra have been added to the collection
- 131 revised and improved BP monographs
- 11 new BPCRS have been produced and referenced
- All monographs from the Ph. Eur. 11th edition and supplements up to 11.8
- The Ph. Eur. 12th edition, comprising issues 12.1, 12.2 and 12.3, included as in-year online and download updates
Built for your role
Regulatory and scientific affairs
- Speeds up submissions with globally aligned, regulator recognised methods and specifications
Quality assurance and manufacturing
- Meet batch-release and GMP expectations with validated, audit-ready standards
Clinical operations and pharmacology
- Ensure IMP consistency and analytical integrity across global sites
Bioanalytics and R&D teams
- Reduce variability and improve reproducibility with harmonised methods
